Evidence map›Paper›PMID 41282100›Full record

ArticleResearch square2025

Synergistic Inhibition of PI3K and HSP90 Enhanced Antitumorigenic Efficacy in Adrenocortical Carcinoma.

Prachi Mishra, Brieann Sobieski, Dipranjan Laha, Steven D Forsythe, Min Shen, Ya-Qin Zhang, Mathew Hall, Bhavishya Ramamoorthy, Rob Grant, Nicholas L Michael and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Prachi MishraSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Brieann SobieskiSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Dipranjan LahaSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Steven D ForsytheSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Min ShenChemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Ya-Qin ZhangChemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Mathew HallChemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Bhavishya RamamoorthySurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rob GrantSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nicholas L MichaelSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Samira M SadowskiSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jaydira Del RiveroDevelopmental Therapeutics Branch, National Cancer Institute. National Institutes of Health, Bethesda, MD, USA.
Jonathan M HernandezSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Naris NilubolSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

Investigating the role of DNA breaks in mammalian agingZIABC011283 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI OBERDOERFFER, PHILIPP · 2010 to 2019
$4.3M
Intramural NIH HHS ZIA BC011283
6 · The paper itself

Abstract

Adrenocortical cancer (ACC) is a rare and aggressive malignancy with poor survival due to a lack of effective treatments; therefore, it is important to identify therapies to be readily studied in clinical trials. Quantitative high-throughput drug combination screening identified potent synergy between phosphatidylinositol-3-kinase (PI3K) inhibitor, PIK75 and heat shock protein 90 (HSP90) inhibitors, Ganetespib (STA9090), HSP990, or Luminespib (NVP-AUY922). Preclinical

Indexed as

Adrenocortical cancercombination therapyHeat shock protein 90PI3Kquantitative high-throughput drug screening

Identifiers

PMID41282100
PMCPMC12636729

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.